Article Text

Download PDFPDF
Extended report
Type I interferon system activation and association with disease manifestations in systemic sclerosis
  1. Maija-Leena Eloranta1,
  2. Karin Franck-Larsson1,2,
  3. Tanja Lövgren1,
  4. Sebastian Kalamajski3,
  5. Anders Rönnblom1,
  6. Kristofer Rubin3,
  7. Gunnar V Alm4,
  8. Lars Rönnblom1
  1. 1Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  2. 2Wyeth AB, Solna, Sweden
  3. 3Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
  4. 4Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden
  1. Correspondence to Dr Maija-Leena Eloranta, Department of Medical Sciences, Clinical Research Department 3, Systemic Autoimmunity Group, Entrance 85, 3rd Floor, Uppsala University Hospital, Uppsala S-75185, Sweden; maija-leena.eloranta{at}medsci.uu.se

Footnotes

  • Funding The work was supported by grants from the Dana Foundation, the Swedish Research Council, the Swedish Society of Medicine, the Swedish Rheumatism Association, the Swedish Cancer Foundation, the Uppsala University Hospital Development Foundation, the Agnes and Mac Rudberg Foundation, the Nilsson Foundation, the King Gustaf V 80-year Foundation and COMBINE.

  • Competing interests None.

  • Ethics approval The study was approved by the ethical committee in Uppsala and informed consent was obtained from all patients and controls.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The work was supported by grants from the Dana Foundation, the Swedish Research Council, the Swedish Society of Medicine, the Swedish Rheumatism Association, the Swedish Cancer Foundation, the Uppsala University Hospital Development Foundation, the Agnes and Mac Rudberg Foundation, the Nilsson Foundation, the King Gustaf V 80-year Foundation and COMBINE.

  • Competing interests None.

  • Ethics approval The study was approved by the ethical committee in Uppsala and informed consent was obtained from all patients and controls.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.